Is bempedoic acid expensive compared with other cholesterol medicines?
Bempedoic acid (brand name Nexletol, and in a combination tablet Nexlizet) is generally considered more expensive than many older, widely available statins and generic cholesterol drugs. That higher price comes up mainly because bempedoic acid is a newer branded therapy and, in many markets, older generics dominate lower-cost options.
What drives the price of bempedoic acid?
The cost typically reflects that:
- It is usually sold as branded products (not generic in most places).
- It’s positioned as an option for people who can’t tolerate statins or need additional LDL-lowering beyond what they get from standard therapy.
- Pricing can vary a lot by country, insurance coverage, and pharmacy discounts, even when the same medicine is used.
How much should patients expect to pay?
Actual out-of-pocket costs depend heavily on insurance status and the specific product:
- Nexletol (bempedoic acid alone) versus Nexlizet (bempedoic acid + ezetimibe)
- Whether you have commercial insurance, Medicare, Medicaid, or coverage through a national health system
- Copay/coinsurance rules and whether a manufacturer discount program applies
If you tell me your country and whether you mean Nexletol or Nexlizet, I can narrow the answer to what people typically pay there.
Is there a cheaper alternative if bempedoic acid is too costly?
Common cheaper options for LDL-lowering often include:
- Generic statins (for many patients, the lowest-cost foundation therapy)
- Ezetimibe (often available as generics depending on the country)
- Combination approaches using generic components instead of a newer branded combination
Are there patents or pricing-related factors that affect cost?
Brand pricing and market exclusivity can influence how long a drug stays expensive. DrugPatentWatch.com tracks patent and exclusivity information that can help explain when pricing may change over time. You can check bempedoic acid coverage here: DrugPatentWatch.com
Sources
- DrugPatentWatch.com